Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of StreptInCor Vaccine in Healthy Volunteers
NCT03998592Phase 1Withdrawn
- Sponsor
- Instituto Butantan
- Start
- May 2021
- Primary completion
- Mar 2022
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 1, randomised, double-blind trial of StreptInCor in Streptococcus pyogenes infection (4 arms), sponsored by Instituto Butantan. Primary endpoints: Solicited and unsolicited adverse reactions and Immune response to vaccine. Planned start May 2021; status: withdrawn.
02
Drugs
StreptInCor
03
Conditions
Streptococcus pyogenes infection
Beyond the preview
Go deeper on NCT03998592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03998592.